论文部分内容阅读
目的探讨瑞替普酶与尿激酶溶栓治疗急性ST段抬高型心肌梗死(STEMI)临床疗效及安全性。方法对2010年1月1日~2013年12月31日收治的96例临床确诊的急性ST段抬高型心肌梗死，随机分组各48例采用瑞替普酶(治疗组)与尿激酶(对照组)行溶栓治疗，观察30、60、120min再通率、死亡率、不良反应发生率。结果瑞替普酶组30、60、90、120min开通率明显高于尿激组差异有统计学意义(0.05)。结论瑞替普是治疗急性ST段抬高型心肌梗死安全有效的溶栓药，疗效优于尿激酶。“,”Objective To explore the clinical ef icacy and safety of Reteplase for Injection and Urokinase for Injection treated in patients with STEMI.Methods 96 patients with STEMI were divided into Reteplase group and Urokinase group randomly from Jan.1.2010 to Dec.31.2013,and ervey group was 48 cases.The clinical def ect and death rate and adverse reaction incidence rate was compared between the two groups during 30,60,90,120 minutes.Results There was significantly dif erence of clinical def ect between the two groups ( 0.05).Conclusion The Reteplase is ef ectcy and safety dugs,is bet er than the Urokinase.